New insights into the clinical management of advanced gastrointestinal stromal tumors

References

• Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21(23):4342–4349.
   PubMed Web of Science ®Google Scholar
• Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC soft tissue and bone sarcoma group. Eur J Cancer. 2004;40(5):689–695.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Rankin C, Blanke CD, et al. Correlation of long-term results of imatinib in advanced gastrointestinal stromal tumors with next-generation sequencing results: analysis of phase 3 SWOG intergroup trial S0033. JAMA Oncol. 2017;3(7):944–952.
   PubMed Web of Science ®Google Scholar
• Van Glabbeke MM, Owzar K, Rankin C, et al. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta-analysis based on 1,640 patients (pts). J Clin Oncol. 2007;25(18_suppl):10004.
   Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006;24(29):4764–4774.
   PubMed Web of Science ®Google Scholar
• Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology. 2005;128(2):270–279.
   PubMed Web of Science ®Google Scholar
• Tamborini E, Pricl S, Negri T, et al. Functional analyses and molecular modeling of two c-KIT mutations responsible for imatinib secondary resistance in GIST patients. Oncogene. 2006;25(45):6140–6146.
   PubMed Web of Science ®Google Scholar
• Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res. 2006;12(6):1743–1749.
   PubMed Web of Science ®Google Scholar
• Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005;11(11):4182–4190.
   PubMed Web of Science ®Google Scholar
• Theou N, Gil S, Devocelle A, et al. Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib. Clin Cancer Res. 2005;11(21):7593–7598.
   PubMed Web of Science ®Google Scholar
• Rossi F, Yozgat Y, de Stanchina E, et al. Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib. Mol Cancer Res. 2010;8(9):1271–1283.
   PubMed Web of Science ®Google Scholar
• Cohen NA, Zeng S, Seifert AM, et al. Pharmacological inhibition of KIT activates MET signaling in gastrointestinal stromal tumors. Cancer Res. 2015;75(10):2061–2070.
   PubMed Web of Science ®Google Scholar
• Ran L, Sirota I, Cao Z, et al. Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth. Cancer Discov. 2015;5(3):304–315.
   PubMed Web of Science ®Google Scholar
• Javidi-Sharifi N, Traer E, Martinez J, et al. Crosstalk between KIT and FGFR3 promotes gastrointestinal stromal tumor cell growth and drug resistance. Cancer Res. 2015;75(5):880–891.
   PubMed Web of Science ®Google Scholar
• Antonescu CR, Romeo S, Zhang L, et al. Dedifferentiation in gastrointestinal stromal tumor to an anaplastic KIT-negative phenotype: a diagnostic pitfall: morphologic and molecular characterization of 8 cases occurring either de novo or after imatinib therapy. Am J Surg Pathol. 2013;37(3):385–392.
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Cooke L, Riley C, et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene. 2007;26(27):3909–3919.
   PubMed Web of Science ®Google Scholar
• Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer. 2005;41(12):1751–1757.
   PubMed Web of Science ®Google Scholar
• Kang YK, Ryu MH, Yoo C, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1175–1182.
   PubMed Web of Science ®Google Scholar
• Morgan A, Demetri GS, Fletcher JA, et al. Patients with imatinib mesylate-resistant GIST exhibit durable responses to sunitinib malate (SU11248). Eur J Cancer. 2005;Supplements 3:421.
   Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, et al., Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 368(9544): 1329–1338. 2006. .
   PubMed Web of Science ®Google Scholar
• Reichardt P, Kang YK, Rutkowski P, et al. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer. 2015;121(9):1405–1413.
   PubMed Web of Science ®Google Scholar
• George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer. 2009;45(11):1959–1968.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Maki RG, Corless CL, et al. Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. J Clin Oncol. 2006;24(18_suppl):9502.
   Web of Science ®Google Scholar
• Reichardt P, Demetri GD, Gelderblom H, et al. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. BMC Cancer. 2016;16:22.
   PubMed Web of Science ®Google Scholar
• George S, Wang Q, Heinrich MC, et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol. 2012;30(19):2401–2407.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Reichardt P, Kang YK, et al., Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 381(9863): 295–302. 2013. .
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Jones RL, von Mehren M, et al. Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA exon 18 gastrointestinal stromal tumors (GIST). J Clin Oncol. 2019;37(15_suppl):11022.
   Web of Science ®Google Scholar
• Blay JY, Serrano C, Heinrich MC, et al., Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial [published correction appears in Lancet Oncol. 2020 Jul;21(7):e341]. Lancet Oncol. 21(7): 923–934. 2020. .
   PubMed Web of Science ®Google Scholar
• Kettle JG, Anjum R, Barry E, et al.. Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors. J Med Chem. 2018 Oct 11;61(19):8797–8810.
   PubMed Web of Science ®Google Scholar
• Bauer S, Yu LK, Demetri GD, et al.. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res. 2006;66:9153–9161.
   PubMed Web of Science ®Google Scholar
• Doi T, Kurokawa Y, Sawaki A, et al.. Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial. Eur J Cancer. 2019 Nov;121:29–39.
   PubMed Web of Science ®Google Scholar
• Pantaleo MA, Tarantino G, Agostinelli C, et al.. Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response. Oncoimmunology. 2019 Jun 4;8(9):e1617588.
   PubMed Web of Science ®Google Scholar
• Cavnar MJ, Zeng S, Kim TS, et al.. KIT oncogene inhibition drives intratumoral macrophage M2 polarization. J Exp Med. 2013;210(13):2873–2886.
   PubMed Web of Science ®Google Scholar
• Zhang JQ, Zeng S, Vitiello GA, et al.. Macrophages and CD8+ T cells mediate the antitumor efficacy of combined CD40 ligation and imatinib therapy in gastrointestinal stromal tumors. Cancer Immunol Res. 2018;6(4):434–447.
   PubMed Web of Science ®Google Scholar
• D’Angelo SP, Shoushtari AN, Keohan ML, et al.. Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas: A phase Ib study of dasatinib plus ipilimumab. Clin Cancer Res. 2017;23(12):2972–2980.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Jones RL, von Mehren M, et al., Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial [published correction appears in Lancet Oncol. 2020 Sep;21(9):e418]. Lancet Oncol. 21(7): 935–946. 2020. .
   PubMed Web of Science ®Google Scholar
• von Mehren M, Tetzlaff ED, Macaraeg M, et al.. Heinrich Dose escalating study of crenolanib besylate in advanced GIST patients with PDGFRA D842V activating mutations. J clin oncol. 2016 May 20;34(15_suppl):11010–11101.
   Web of Science ®Google Scholar
• Hostein I, Faur N, Primois C, et al.. BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol. 2010;133(1):141–148.
   PubMed Web of Science ®Google Scholar
• Falchook GS, Trent JC, Heinrich MC, et al.. BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget. 2013 Feb 4;2:310–315. DOI:10.18632/oncotarget.864
   PubMedGoogle Scholar
• Boikos SA, Pappo AS, Killian JK, et al., Molecular Subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors: a report from the national institutes of health gastrointestinal stromal tumor clinic. JAMA Oncol. 2(7): 922–928. 2016.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) - a review. Int J Biochem Cell Biol. 2014;53:514–519.
   PubMed Web of Science ®Google Scholar
• Killian JK, Kim SY, Miettinen M, et al.. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov. 2013;3(6):648–657.
   PubMed Web of Science ®Google Scholar
• McWhinney SR, Pasini B, Stratakis CA. et al.. Syndrome consortium. Familial gastrointestinal stromal tumors and germ-line mutations. N Engl J Med. 2007;357(10):1054–1056.
   PubMed Web of Science ®Google Scholar
• Carney JA, Sheps SG, Go VL, et al.. The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. N Engl J Med. 1977;296(26):1517–1518.
   PubMed Web of Science ®Google Scholar
• Carney JA, Stratakis CA. Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. Am J Med Genet. 2002;108(2):132–139.
   PubMed Web of Science ®Google Scholar
• Szucs Z, Thway K, Fisher C, et al.. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. Future Oncol. 2017;13(1):93–107.
   PubMed Web of Science ®Google Scholar
• Ricci R. Syndromic gastrointestinal stromal tumors. Hered Cancer Clin Pract. 2016;14:15.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Killian JK, Wang ZF, et al.. Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation. Am J Surg Pathol. 2013;37(2):234–240.
   PubMed Web of Science ®Google Scholar
• Mei L, Smith SC, Faber AC, et al.. Gastrointestinal stromal tumors: the GIST of precision medicine. Trends Cancer. 2018;4(1):74–91.
   PubMed Web of Science ®Google Scholar
• Haller F, Moskalev EA, Faucz FR, et al.. Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad. Endocr Relat Cancer. 2014;21(4):567–577.
   PubMed Web of Science ®Google Scholar
• Boikos SA, Xekouki P, Fumagalli E, et al.. Carney triad can be (rarely) associated with germline succinate dehydrogenase defects. Eur J Hum Genet. 2016;24(4):569–573.
   PubMed Web of Science ®Google Scholar
• Beadling C, Patterson J, Justusson E, et al. Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA. Cancer Med. 2013;2:21–31.
   PubMed Web of Science ®Google Scholar
• Belinsky MG, Rink L, Flieder DB, et al. Over expression of insulin-like growth factor 1 receptorand frequentmutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2013;52:214–224.
   PubMed Web of Science ®Google Scholar
• Pantaleo MA, Astolfi A, Di Battista M, et al. Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target. Int J Cancer. 2009;125:2991–2994.
   PubMed Web of Science ®Google Scholar
• von Mehren M, George S, Heinrich MC, et al.. Linsitinib (OSI-906) for the treatment of adult and pediatric wild-type gastrointestinal stromal tumors, a SARC Phase ii study. Clin Cancer Res. 2019. DOI:10.1158/1078-0432
   PubMed Web of Science ®Google Scholar
• Drilon A, Laetsch TW, Kummar S, et al.. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018Feb22;378(8):731–739.
   PubMed Web of Science ®Google Scholar
• Doebele RC, Drilon A, Paz-Ares L, et al.. trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020 Feb;21(2):271–282.
   PubMed Web of Science ®Google Scholar